Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
176 hedge funds and large institutions have $374M invested in Sage Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 67 increasing their positions, 51 reducing their positions, and 33 closing their positions.
155% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $1.55M
31% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 51
4.71% less ownership
Funds ownership: 88.95% → 84.24% (-4.7%)
10% less funds holding
Funds holding: 195 → 176 (-19)
36% less capital invested
Capital invested by funds: $581M → $374M (-$208M)
58% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.6M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.66M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.13M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$3.02M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.61M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6M |
| 3 |
Morgan Stanley
New York
|
-$5.33M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$5.31M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.25M |
SAGE Hedge Fund Activity: Q3 2024 in Review
176 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2024, worth a combined $374M — down 36% from $581M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of SAGE and 14 opened new positions — a net loss of 19 holders — while 51 trimmed existing stakes and 67 added.
The largest buyer was Millennium Management, adding an estimated $11.6M. The largest seller was JP Morgan Chase, cutting an estimated $9.61M.
- 176 institutional investors held Sage Therapeutics (SAGE) as of Q3 2024, down from 195 in Q2 2024.
- Funds reported $374M of Sage Therapeutics stock for Q3 2024, down 36% quarter-over-quarter.
- 14 funds opened new Sage Therapeutics positions in Q3 2024 and 33 closed out, a net change of -19 holders.
- The largest Sage Therapeutics buyer in Q3 2024 was Millennium Management, an estimated $11.6M added.
- The largest Sage Therapeutics seller in Q3 2024 was JP Morgan Chase, an estimated $9.61M sold.
Based on aggregated 13F filings for Q3 2024.